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There is broad and compelling evidence for risk factor reduction to limit cardiovascular morbidity and mortality in
patients with peripheral arterial disease. Indeed, vascular surgeons have placed a call to arms to ensure this takes place.
Despite this fact, some wariness exists on the part of many vascular surgeons to initiate these strategies, functionally
abnegating their responsibilities in this regard. The purpose of this article is to provide a simple reference to guide
effective therapies for overall cardiovascular risk reduction in patients with peripheral arterial disease. Specific recom-
mendations are made for tobacco cessation, lipid-lowering therapy, antiplatelet therapy, blood pressure control, and
maintenance of normoglycemia. (J Vasc Surg 2008;47:1108-15.)The systemic ravages of atherosclerosis impact signifi-
cantly on patients with peripheral arterial disease (PAD),
who incurr an annual risk of a cardiovascular event of 5% to
7%.1 The presence of PAD, even in the absence of a history
of coronary artery disease (CAD), confers the same relative
risk of a death from cardiovascular cause as in patients with
a previous cardiovascular event.2,3 As such, PAD is consid-
ered a CAD equivalent, and the American Heart Associa-
tion (AHA), National Heart, Lung and Blood Institute,
and the National Cholesterol Education Program (NCEP)
recommend identical atherosclerotic risk reduction strate-
gies for PAD and CAD patients.4-6 Risk factor modification
includes therapeutic lifestyle changes, antiplatelet therapy,
lipid modification, control of hypertension, smoking cessa-
tion, and glycemic control in diabetic patients.
Although these tenets are understood well and even
promoted7-9 by vascular surgeons, there is significant un-
ease in initiating specific medical therapies.10,11 The pur-
pose of this article is to provide a simple reference to initiate
treatment for overall cardiovascular risk reduction in pa-
tients with PAD. Specific recommendations are made for
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1108tobacco cessation, lipid-lowering therapy, antiplatelet ther-
apy, blood pressure control, andmaintenance of normogly-
cemia.
THERAPEUTIC LIFESTYLE CHANGES
All patients with PAD should undergo lifestyle modifi-
cations to limit their overall cardiovascular risk, as sug-
gested by the AHA.12 Such maneuvers include consump-
tion of an overall healthy diet, weight loss to achieve a
target body mass index25, reductions in dietary total and
saturated fat, and daily aerobic exercise. Weight loss pro-
vides decreases in low-density lipoprotein (LDL) choles-
terol up to 40%, reduces serum triglycerides by 22%, and
raises high-density lipoprotein (HDL) by as much as 9%.13
Randomized data show that diet and exercise reduce lipid
levels14,15 and cardiovascular events16; however, most pa-
tients will require additive pharmacotherapy to achieve
goals for blood pressure17 and lipids.4
Tobacco dependence
Background for intervention and therapeutic goals.
More than 80% of patients with PAD are current or former
smokers.18 Smoking cessation decreases the mortality rate
by more than one-third in patients with CAD.19,20 Indeed,
the benefit of quitting smoking on mortality reduction is
likely greater than the other risk management strategies
that will be discussed. In contrast, smoking reduction does
not appear to reduce all-cause mortality.21 In fact, smoking
as few as 1 to 4 cigarettes a day substantially increases the
risk of cardiovascular and all-cause mortality.22 Clearly, the
goal for PAD patients who smoke is complete and lifelong
cessation.
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bacco cessation strategy include patient motivation, recur-
rent and timely physician advice (at each visit), behavioral
therapy, and pharmacotherapy. Vascular surgeons have a
unique opportunity to initiate cessation strategies. Patients
often present to us in a vulnerable state, concerned over a
life- or limb-threatening disorder. Reinforcement of the
pernicious effects of smoking and its association with pro-
gression of disease, limb loss, and death may be particularly
motivating under these conditions.
Behavioral therapy. Perhaps surprisingly to us as sur-
geons, tobacco dependence counseling is quite successful
in helping patients quit smoking, whether administered in
an individual, group, or telephone setting. Its effectiveness
increases directly with duration of treatment time, but as
little as 3 minutes of counseling helps patients quit.23,24 It
is increasingly available at little or no cost through local
communities, insurers, and managed care organizations.
These sessions may include education, suggestions for ta-
Table I. Pharmacotherapeutic agents for smoking cessatio
Bupropion SR
7-12 wks
Treatment period
Details Take for 1-2 wks before quitting; may use
maintenance for up to 6 months
Dosage Days 1-3: 150 mg q day; days 4-end: 150
Pros Easy to use; reduces urge to smoke
Cons May disturb sleep, may cause dry mouth
Caution Do not use if seizure disorder, an eating d
or are taking a monoamine oxidase inhib
Availability Prescription only
Cost/day for
average usea
$2.33
BID, Twice daily; q, once daily.
aValues obtained from drugstore.com.pering, and various coping mechanisms for assistance withrelapse prevention. Quit rates at 1 year are approximately
20% for patients who complete a program25-27; however,
maximal quit rates are obtained when a multimodality ap-
proach is used. In addition to behavioral therapy, all smokers
should be offered one of six medications with an established
empiric record of efficacy in smoking cessation (Table I).
Pharmacotherapy
Nicotine replacement therapy. Nicotine is a potent
psychoactive drug. After long-term use, its absence leads
not only to the loss of the euphoric effects of the drug but
also to symptoms of withdrawal. These may include dys-
phoria, depression, insomnia, anxiety, irritability, restless-
ness, and weight gain. Nicotine replacement therapy
(NRT) helps curb some of these symptoms while the
patient is undergoing concurrent behavioral therapy. Nic-
otine replacement therapy is safe28 and does not increase
cardiac risk even in patients who continue to smoke while
using the patch.29 Nicotine replacement therapy does not
Varenicline
12 wks
Take for 1 wk before quitting; may use for maintenance
for up to 6 months
ID Days 1-3: 0.5 mg q day; days 4-7: 0.5 mg BID; days
7-end 1 mg BID
Easy to use; reduces urge to smoke
30% of patients experience nausea; should be taken with
food; may disturb sleep
r, Reduce dose if creatine clearance 30 mL/min
Prescription only
$3.57n
for
mg B
isorde
itorinduce platelet aggregation, elevations in fibrinogen, coro-
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heart rate or blood pressure that are associated with
smoking.30
Nicotine replacement is available in gum, lozenge,
transdermal patch, nasal spray (Nicotrol NS; Pharmacia,
Helsingborg, Sweden), and inhaler (Nicotrol Inhaler,
Pharmacia). All have similar efficacy in the promotion of
smoking cessation, increasing the odds of quitting 1.5- to
2-fold.31 This benefit occurs even in the absence of sup-
portive behavioral therapy. Slightly higher quit rates have
been demonstrated with higher doses of the patch and
gum, particularly in heavier smokers. For most patients,
quit rates of 40% to 60% can be expected at the conclusion
of a behavior therapy program combined with NRT ther-
apy, decreasing to 25% to 30% at 1 year.24
Bupropion SR. Bupropion is an atypical antidepressant
with both dopaminergic and adrenergic actions. The sus-
tained release form of the drug became available in 1998
specifically targeted at assisting with smoking cessation
Table I. Continued.
Nicotine rep
Patch Gu
6-8 wks
Up
(May use f
n
Treatment period
One patch/d; taper dose if using: 21 mg for 4 wks;
14 mg for 2 wks; 7 mg for 2 wks. No taper if
using 15 mg for 8 wks; light smokers (10 cig/d)
can start with lower dose
2 mg; 4 m
smokers
1-2 h (1
many do
enough
Easy to use; ready dose of nicotine Patient co
helps wi
urges (e
keeps m
May irritate skin; may disturb sleep; cannot adjust
amount of nicotine in response to urges
Need to ch
“chew a
should n
beverag
chewing
Do not use if severe uncontrolled eczema or
psoriasis
Caution w
Over the counter Over the c
mint, or
Brand name, $3.21; store brand, $2.19 Brand nam
brand, $(Zyban; Glaxo SmithKline, Research Triangle Park, NC).It can be used in patients who have failed or are intolerant
of NRT, unaccompanied as first-line therapy, or combined
with NRT.32 Treatment with bupropion SR doubles quit
rates at 1 year vs placebo.33 Evidence suggests that mono-
therapy with bupropion is superior to NRT alone32 and
that the addition of NRT to bupropion adds little to over-
all efficacy.34 In general, bupropion is dosed twice daily
(Table I); however, once-daily dosing may be equally effec-
tive and better tolerated.35 Bupropion lowers the threshold
for seizures and thus is contraindicated in patients with a
seizure disorder but is overall quite safe. Themost common
side effects are insomnia, dry mouth, and nausea.
Varenicline. Varenicline (Chantix; Pfizer; Mission,
KS) is a partial agonist of the 42 nicotinic acetylcholine
receptor. It works by stimulating dopamine release in the
brain, but to a lesser degree than nicotine, and blocks
nicotine from binding to the nicotine receptor. This results
in relief of nicotine withdrawal symptoms and cigarette
cravings as well as decreases the reinforcement and reward
ent therapy
enge Inhaler Nasal spray
wks
ger time as
) 3-6 wks 3-6 wks
Taper use over last few
weeks
Taper use over last few
weeks
avy
iece every
pieces/d);
use
6-16 cartridges/d;
need to inhale about
80 times to use up
cartridge; can use
part of cartridge and
save the rest for later
that day
One dose  1 squirt
to each nostril; dose
1-2 times/h as
needed; min 8
doses/d; max  40
doses/d
the dose;
edictable
er meals);
busy
Patient controls the
dose; helps with
predictable urges;
keeps hands and
mouth busy
Patient controls the
dose; fastest acting
for relief of urges
orrectly—
rk”;
ink acidic
ile
May irritate mouth
and throat
(improves with use);
does not work well
40°; should not
drink acidic
beverages while
using inhaler
Need to use correctly
(do not inhale it);
may irritate nose
(improves with use);
may cause
dependence
ntures May induce
bronchospasm,
consider patch in
patients with
reactive airway
disease
May induce
bronchospasm,
consider patch in
patients with
reactive airway
disease
er (regular,
ge)
Prescription only Prescription only
.50; store $8.22 (10 cartridges/d) $4.08 (12 doses/d)lacem
m/loz
to 12
or lon
eeded
g (he
); 1 p
0-15
not
ntrols
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2.18associated with smoking. The United States Food and
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smoking cessation in May 2006. It appears to increase the
chance of successful quitting nearly threefold.36 In clinical
studies, varenicline appears to have a slight advantage in
continuous abstinence rates over bupropion SR at 3 and 6
months, but perhaps less so at later intervals.37-39 In addi-
tion, 24 weeks of varenicline improves continuous absti-
nence rates at 6months and 1 year compared with 12 weeks
of therapy.40 These benefits come at some expense: vareni-
cline costs nearly twice as much as bupropion SR and NRT.
Serious side effects are rare, and no contraindications or
drug–drug interactions have been identified for vareni-
cline. Up to 30% of patients experience mild to moderate
nausea that can be reduced by taking the medication after
eating or with a full glass of water.
Recommendations. In combination with targeted,
personal physician advice and referral to behavioral therapy,
we recommend bupropion SR at 150mg/d for 3 days, then
150mg twice daily for 7 weeks. The patient’s intended quit
date should be 1 week after the initiation of bupropion.
Nicotine replacement therapy may be added to this regi-
men for the heaviest of smokers.
Hyperlipidemia
Background for intervention. Epidemiologic and
prospective observational cohort studies have shown a
graded correlation between serum cholesterol and the risk
of coronary events.41 Several subsequent large, prospective
randomized trials42-45 and meta-analysis46 have confirmed
that statin use results in a 20% to 30% reduction in cardio-
vascular and all-cause mortality in patients with CAD.47
Furthermore, statin pleiotropism in producing beneficial
effects is nearly legendary, with known effects on athero-
sclerotic plaque stabilization and reduction in oxidative
stress and vascular inflammation.48
Therapeutic goals. In general, recommendations for
the treatment of hyperlipidemia are based upon the LDL
cholesterol (LDL-C) fraction. The AHA/American Col-
lege of Cardiology (ACC) guidelines published in 2006
recommend a LDL goal of 100 mg/dL for all patients
with PAD.1 Themodified Third Report of the Expert Panel
on Detection, Evaluation and Treatment of High Blood
Cholesterol in Adults (Adult Treatment Panel III or ATP
Table II. Comparison of lipid-lowering agents
Drug Atorvastatin53 Fluvastatin L
Trade name Lipitor Lescol Mev
Common dose range 10-80 mg/d 20-80 mg/d 1
Lipid level change, %
Total cholesterol () 27-39 () 17-25
LDL () 37-51 () 22-35
HDL () 2-6 () 3-7
Triglycerides () 20-28 () 17-25
Cost (#30, 20 mg)a $109.19 $74.72
LDL, Low-density lipoprotein; HDL, high-density lipoprotein.
aValues obtained from drugstore.com.III) guidelines, published in 2004, recommended an op-tional LDL goal of 70 mg/dL for “very-high-risk” pa-
tients.5 The 2005 ACC/AHA guidelines define “very-
high-risk” PAD patients as those with multiple risk factors
(especially diabetes), severe or poorly controlled risk factors
(especially smoking), and risk factors of the metabolic
syndrome (especially elevated triglycerides in the face of an
elevated non-HDL/HDL ratio).1 Moreover, a recent pro-
spective observational cohort study of nearly 1400 PAD
patients showed that intensive therapy with statins target-
ing an LDL 70 mg/dL improved overall and cardiac
mortality at a mean follow-up of 6 years.49
Although therapeutic lifestyle changes are important to
all patients, we do not believe in withholding drug therapy
in patients with PAD with total cholesterol 135 mg/dL.
Statins (3-hydroxy-3-methylglutaryl coenzyme A [HMG-
CoA] reductase inhibitors) are the only class of lipid-
lowering drugs shown to decrease overall mortality in pri-
mary and secondary prevention of coronary events. The
PAD-specific, cholesterol-independent pleiotropic effects
of statins are also well known and include improvements in
leg functioning, ankle-brachial index, walking perfor-
mance, symptoms of claudication, and perioperative and
long-term mortality.50-52 Thus, statins serve as the primary
foundation for effective lipid reduction in patients with
PAD.
Choice of agent and dosage. Statins range in po-
tency, reducing LDL between 20% and 55% (Table
II).53,54 The choice of which statin to initiate is determined
by cost, availability within a formulary, potency, and effects
on other triglyceride and HDL levels. Currently, three
statins are available generically: lovastatin (Mevacor, Merck
& Co Inc, Whitehouse Station, NJ), pravastatin (Prava-
chol, Bristol-Myers Squibb, New York, NY), and simvasta-
tin (Zocor, Merck & Co, Inc). Atorvastatin (Lipitor, Pfizer
Inc, New York, NY) retains a lead in overall United States
sales and is slated to become available generically by 2011.
Rosuvastatin (Crestor, AstraZeneca, London, United
Kingdom) is the newest and most potent of the statins.
Considering potency, efficacy, and cost, we recom-
mend simvastatin at 40 mg/d for the initiation of lipid-
lowering therapy in PAD patients. A fasting lipid profile is
obtained at baseline and 6 weeks. Although clear-cut data
on routine monitoring do not exist, ATP III recommends
atin54 Pravastatin53 Rosuvastatin53 Simvastatin53
Altoprev Pravachol Crestor Zocor
mg/d 10-80 mg/d 10-80 mg/d 5-80 mg/d
6-29 () 15-22 () 33-40 () 20-33
4-40 () 20-30 () 46-55 () 28-46
-10 () 3-6 () 8-10 () 5-7
0-19 () 8-13 () 20-26 () 12-18
.99 $17.99 $100.47 $27.99ovast
acor/
0-80
() 1
() 2
() 7
() 1
$22follow-up every 6 weeks until LDL targets are achieved.4 If
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may be increased to the maximum approved dose of 80
mg/d. It should be noted that the titration from simvasta-
tin from 40 mg/d to 80 mg/d confers a small benefit of an
additional 8% reduction in LDL and may increase risk of
creatine phosphokinase level elevations. For the patient
who fails to achieve LDL goals, options include switching
to a more potent statin or adding ezetimibe at 10 mg/d
(Zetia, Schering-Plough Corp, Kenilworth, NJ). A fasting
lipid profile should be obtained 6 weeks after changes in
medication or dose are made. Once at goal, fasting lipid
levels should be monitored every 6 to 12 months.
Side effects and contraindications. Statins are well
tolerated, with overall good patient adherence and compli-
ance.55 Side effects may include diarrhea, abdominal pain,
myalgias, and elevations in liver enzymes. Rhabdomyolysis
is rare. Patients should be instructed to notify you if muscle
aches develop. If a myopathy develops, consideration of an
alternative statin may be appropriate. Pravastatin and fluva-
statin may have a lower risk of producing myopathy. Liver
function tests should be obtained at baseline, 8 to 12 weeks
after initiation or elevation in dose, and then annually.
Recommendations. We recommend simvastatin,
40 mg/d initially, with a fasting lipid profile at 6 weeks
titrating upward to reach goal of an LDL 70 mg/dL.
Check liver function tests at baseline and 12 weeks.
Antiplatelet therapy
Platelets are pivotal in nearly all events leading to a
cardiovascular death. Aspirin’s irreversible inactivation of
cyclooxygenase 1 (COX-1) prevents platelet conversion of
prostaglandin H2 to thromboxane A2, thus inhibiting
platelet aggregation. The Antithrombotic Trialists’ Collab-
oration analyzed the results of 195 randomized trials of
antiplatelet agents use in 135,000 high-risk patients,
concluding that antiplatelet treatment resulted in an overall
22% reduction in subsequent myocardial infarction (MI),
stroke, or vascular death.56
The benefits of aspirin have been shown in prospective
randomized trials with doses ranging from 75 to 1500
mg/d; however, higher aspirin doses seem to afford mini-
mal further benefit at the expense of gastrointestinal intol-
erance. Furthermore, higher doses result in the potentially
harmful reversible inhibition of endothelial cell synthesis of
prostacyclin, a vasodilator and inhibitor of platelet aggre-
gation. A recent systematic review concluded that aspirin
dosages75 to 81 mg/d provided no additive efficacy but
increased risks of bleeding predominantly from gastrointes-
tinal toxicity.57 The formulation of aspirin, whether enteric-
coated, buffered, or regular, does not affect the risk of
clinically significant bleeding58 or its efficacy in producing
platelet inhibition.59
Clopidogrel is a thienopyridine that prevents platelet
aggregation by irreversibly inactivating the adenosine
diphosphate P2Y12 receptor on the platelet surface. The
Clopidogrel versus Aspirin in Patients at Risk of Ischemic
Events (CAPRIE) trial was a prospective, randomized mul-
tinational trial of aspirin (325 mg/d) vs clopidogrel (75mg/d) in 19,185 patients with atherosclerotic vascular
disease.3 In the subgroup of 6452 patients with PAD,
clopidogrel demonstrated a 23.8% relative risk reduction in
risk of subsequent ischemic stroke, MI, or vascular death
compared with therapy with aspirin at 2 years of follow-up.
Although this benefit did reach statistical significance, the
modest absolute improvement (annual event rate 3.71% vs
4.86%) must be balanced against the higher cost.
More recently, the Clopidogrel forHigh Atherothrom-
botic Risk and Ischemic Stabilization, Management, and
Avoidance (CHARISMA) trial compared the effects of a
dual antiplatelet therapy with clopidogrel plus low-dose
aspirin vs aspirin alone (75 to 162 mg/d) on the incidence
of cardiovascular events in 15,603 patients at high risk for
atherothrombotic events followed up for a median of 28
months.60 The primary efficacy end point, a composite of
MI, stroke, or death from cardiovascular causes, was not
significantly different between the two treatment arms.
However, in a subset of 9478 patients with previous MI,
ischemic stroke, or symptomatic PAD, combination ther-
apy with clopidogrel plus aspirin showed a significant re-
duction in the rate of cardiovascular death, MI, or stroke
(7.3% vs 8.8%), albeit with a significantly higher risk of
transfusion-requiring bleeding.61 In our opinion, the slight
additive benefit is not justified by the increased economic
cost and hemorrhagic risk.
A minority of patients is intolerant of aspirin (gastroin-
testinal upset, ulcer, reactive airway disease, urticaria, ana-
phylaxis). An alternative antiplatelet agent should be cho-
sen for those patients, and clopidogrel is an obvious choice.
It is also important to note that aspirin should be taken at
least 2 hours before other nonsteroidal agents to prevent a
potential deleterious interaction whereby aspirin’s cardio-
protective effects are reduced.
Recommendations. Our recommendation is aspirin,
81 mg /d.
Hypertension
Background. Hypertension is the most common ma-
jor risk factor for premature cardiovascular disease.17 The
Seventh Report of the Joint National Committee on Pre-
vention, Detection, Evaluation, and Treatment of High
Blood Pressure (JNC 7) defined hypertension as a systolic
pressure 140 mm Hg and diastolic blood pressure 90
mm Hg based on the average of two or more reliable
readings.17 Meta-analyses of randomized studies demon-
strate that lowering the blood pressure in patients withmild
to moderate hypertension lowers the risk of stroke by 40%
and of CAD by 16%.62
Therapeutic goals. The ACC/AHA 2005 guidelines
for the management of patients with PAD suggest a target
blood pressure of 140/90 mm Hg.1 For those PAD
patients with concomitant chronic kidney disease, conges-
tive heart failure, or diabetes, the goal should be130/80
mm Hg. Many patients will require more than one medi-
cation to achieve that goal. In fact, JNC 7 recommends the
initiation of two medications if a patient’s blood pressure is
20/10 mm Hg above goal.17
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the cornerstones for antihypertensive management in pa-
tients with PAD: -adrenergic antagonists and angiotensin-
converting enzyme (ACE) inhibitors. The -blockers have
antiarrhythmic, anti-ischemic, and antihypertensive prop-
erties and have been shown to reduce the risk of MI and
death in large-scale prospective trials of patients with
CAD.63 In a meta-analysis of 26 such trials encompassing
nearly 25,000 patients afterMI, -blockade provided a 23%
reduction in mortality vs placebo.64 Although a historic
concern, there are few data to support concerns that
-blockers may worsen symptoms of claudication.65 Con-
traindications to the use of -blockers include sinus brady-
cardia, heart block greater than first degree, and uncom-
pensated congestive heart failure. Selective -blockers may
be used with caution in patients with stable compensated
congestive heart failure, mild to moderate chronic obstruc-
tive pulmonary disease or asthma, and diabetes mellitus.
Evidence for the use of ACE inhibitors in patients with
PAD stems predominantly from the Heart Outcomes Pre-
vention Evaluation (HOPE) trial in which 9297 high-risk
patients without ventricular dysfunction were randomized
to ramipril or placebo. In this study, ramipril reduced the
risk of cardiovascular death, MI, and stroke by 22% during
a 5-year period.66 Subgroup analyses found 4051 of the
9297 patients had a history of PAD, claudication, or an
ankle-brachial index 0.9. This cohort realized a similar
benefit from ramipril compared with those patients without
PAD independent of the effect of ramipril on blood pressure.
The magnitude of this decrement in cardiovascular risk is
equivalent to the benefit seen in other studies from
-blockers, aspirin, or lipid-lowering agents. The most
common side effect of ACE inhibitors is a dry cough. If the
patient is intolerant of ACE inhibition, therapy with an
angiotensin II receptor blocker could be considered. The
cardioprotective effects of angiotensin II receptor blockers
are less well characterized.
Recommendations. We recommend starting with
atenolol, 25 mg daily, and titrating upward to reach a heart
rate of 80 beats/min and a blood pressure of 140/90
(130/80 in patients with diabetes, renal insufficiency, or
heart failure). The maximum suggested dose of atenolol is
100 mg/d. Avoid -blockade if the resting heart rate is
60 beats/min or if the patient has a conduction abnor-
Table III. Suggested initial pharmacotherapy for peripher
Risk factor Goal Drug
Smoking Cessation Bupropion SR
Platelet aggregation Inhibition Aspirin
Hyperlipidemia LDL 70 mg/dL Simvastatin
Hypertension 130/80 Atenolol
Lisinopril
BID, Twice daily; LDL, low-density lipoprotein.
aValues obtained from drugstore.com.
bReduction in myocardial infarction, stroke, or vascular death.mality. Lisinopril should be initiated at a low dose (5 mg)and titrated upward to the preferred dose of 20 mg/d. The
maximum suggested dose of lisinopril is 40 mg/d. It is
recommended to check levels of serum creatinine and
potassium 1 week after initiation of ACE inhibitors.
Diabetes mellitus
Many patients with PAD have diabetes. Indeed, a 1%
increase in hemoglobin A1C correlates with a 28% increase
in PAD incidence and a 28% increased risk of death.67
However, there are little data to support that aggressive
control of blood glucose levels improves risk of MI, stroke,
vascular death, or amputation. We believe the day-to-day
management of diabetes is outside the scope of practice of
most vascular surgeons. Nevertheless, suggestions for dia-
betic foot care and recommendation of a target hemoglo-
bin A1C of 7% should be communicated to the primary
care physician.
CONCLUSION
Vascular surgeons are ideally positioned to intervene on
risk factors in their patients with PAD and have long
championed the medical care of their patients. A vade
mecum—literally, “go with me” from modern Latin—is a
guide at hand for insightful consultation. It is our hope that
this article provides a germane review of the extant litera-
ture and offers vascular surgeons practical, evidence-based
advice to initiate effective therapies that reduce overall
cardiovascular risk in patients with PAD (Table III). These
suggested protocols are broadly applicable to patients in a
vascular practice, since abdominal aortic aneurysm and
symptomatic carotid stenosis are also considered coronary
equivalents.
The responsibility for initiating these risk reduction
strategies in patients shared with a primary care physician
and other cardiovascular specialists is frequently unclear or
awkward; unfortunately, “divided responsibility often leads
to no therapy at all.”68 In the final analysis, we are physi-
cians with specialized knowledge participating in the care of
an underserved population. Despite the global recognition
of the value of risk factor reduction, specific details for
initiating therapy are not widely dispensed. We believe it is
the obligation of the vascular surgeon to initiate these
therapies at the first visit, reinforce compliance at each visit,
tery disease patients
Initial dose Mortality reduction, % Cost/moa
50 mg/d  3 d, then
150 mg BID
33 $69.98
81 mg/d 22b $0.87
40 mg/d 20-30 $49.99
25 mg/d 23 $3.66
5 mg/d 22 $10.99al ar
1and arrange for lifelong follow-up. Failure to make such
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